Login
AstraZeneca PLC logo

AstraZeneca PLC

astrazeneca.com

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Financial Snapshot

Revenue
TTM
$61.37B
Gross Margin
TTM
80.94%
Net Income
TTM
$10.45B
Current Assets
2026 Q2
$27.97B
Current Liabilities
2026 Q2
$31.55B
Current Ratio
2026 Q2
88.63%
Total Assets
2026 Q2
$115.8B
Total Liabilities
2026 Q2
$65.54B
Book Value
2026 Q2
50.30B
Cash
2026 Q2
$4.893B
P/E
TTM
18.88
Free Cash Flow
TTM
$6.044B

Stock Price

Loading...
Market Cap: $197.27 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support